当前位置：首页 > 文献互助 > 互助详情

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer复制

用户bYXunN-iXvoM 1个月前 77 10 已完结

1. 系统已在2026-03-23 15:45:33对应助文件进行删除

2. 如有需要请重新发布求助信息

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI: 10.1001/jama.2024.23560复制

文献链接: https://jamanetwork.com/journals/jama/fullarticle/2828232复制

其他信息:

出版社: American Medical Association (AMA)
作者: Li Chen; Hui Li; Hao Zhang; Huawei Yang; Jun Qian; Zhihua Li; Yu Ren; Shu Wang; Peifen Fu; Hongjian Yang; Yunjiang Liu; Jing Sun; Jianyun Nie; Ruiwen Lei; Yongzhong Yao; Anqin Zhang; Shouman Wang; Xiaopeng Ma; Zhong Ouyang; Hongwei Yang; Song-Yang Wu; Shuo-Wen Cao; Kun Wang; Aimei Jiang; Quchang Ouyang; Da Pang; Limin Wei; Xiaoming Zha; Yu Shen; Xiangwen Qu; Fei Wu; Xiaoyu Zhu; Zhonghua Wang; Lei Fan; Zhi-Ming Shao

上一篇：Exploring potential therapeutic targets for myopia: Causal analysis and biological annotation with gut microbiota

下一篇：Highly efficient and green micro/nano cellulose preparation with micro-nano bubbles from mild alkali pretreated bagasse

互助时间线

2026-03-16 15:45:44 [完结求助]

楼主确认了研究小馆应助的文件是正确的, 求助状态变成 已完结

2026-03-16 15:45:33 [上传文件]

研究小馆上传了文件(pdf 544.53 KB), 求助状态变成 待确认

2026-03-16 15:45:27 [发起求助]

最新发布的求助

Discovery of Potent and Selective Benzothiophene Difluoromethyl Phosphonate (DFMP) PTPN2/N1-Dual Inhibitors 36分钟前
Design and Synthesis of USP1 Inhibitors: Synergistic Antitumor Activity with PARP Inhibitors in Triple-Negative Breast Cancer 1小时前
Design of Cyclic Vinyl Sulfones as WRN Covalent Inhibitors from Noncovalent Binders 1小时前
AutoLead: An LLM-Guided Bayesian Optimization Framework for Multi-Objective Lead Optimization 1小时前
Voltage-Gated Sodium Channels in Pain: Which Channels, Which Blockers, and Where NaV1.7 Fits 3小时前
Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC) 5小时前
Rhabdomyosarcoma spheroids with central proliferation and differentiation 5小时前
Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial 5小时前
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort 5小时前
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs 5小时前
BPI26-027: Multidisciplinary Practice Patterns in HER2-Mutant NSCLC: Insights to Inform Precision Oncology Education 5小时前
ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer 6小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com